Real-World Studies
MACE Incidence Did Not Differ Across TKIs in Chronic Myelogenous Leukemia
Zureigat et alThe oncologist

Clinical trial estimates of cardiotoxicity in chronic myelogenous leukemia (CML) can be limited by selected, healthier study cohorts and short follow-up periods. A study conducted at Cleveland Clinic evaluated the incidence of cardiovascular adverse events (CVD-AE) and secondary echocardiographic alterations in 357 CML patients treated with tyrosine kinase inhibitors (TKIs) between 2007 and 2022, adjusting for prior TKI exposure. Evaluated agents included imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Study outcomes included overall survival, major adverse cardiovascular events (MACE: acute coronary syndrome, heart failure, stroke, peripheral arterial disease, and revascularization), pleural effusions, pericardial effusions, and pulmonary hypertension.
In the study cohort (median age 56 years; 57% male; 85% White), 518 CVD-AE occurred over a median follow-up of 7.2 years. Relative to imatinib, nilotinib was associated with increased acute coronary syndrome (HR 3.5, P = 0.02) and dasatinib was associated with heart failure (HR 2.5, P = 0.04). Dasatinib and asciminib were associated with elevated risks for both pleural effusions (HR 3.5 and 5.8, respectively; P < 0.05) and pericardial effusions (HR 5.1 and 21.6, respectively; P < 0.05). Conversely, dasatinib was associated with lower rates of venous thrombosis (HR 0.1, P = 0.02). Overall MACE incidence did not differ significantly among the evaluated TKIs. In an analysis of 69 patients with serial echocardiographic data, ponatinib was associated with decreased left ventricular ejection fraction (β = -5.2, P = 0.008), and bosutinib was associated with increased global longitudinal strain (β = 3.0, P = 0.037), indicating that cardiovascular risks differ across TKIs and therapy duration influences echocardiographic changes.
Key Takeaways
- Compared with imatinib, nilotinib was associated with increased acute coronary syndrome (HR 3.5, P = 0.02) and dasatinib with increased heart failure (HR 2.5, P = 0.04), whereas overall major adverse cardiovascular event incidence did not differ significantly across tyrosine kinase inhibitors.
- Pleural effusions (HR 3.5 and 5.8; P < 0.05) and pericardial effusions (HR 5.1 and 21.6; P < 0.05) were associated with dasatinib and asciminib, respectively, while dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02).
- Among 69 patients undergoing serial echocardiography, ponatinib decreased left ventricular ejection fraction (β = -5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037).
Read the original sourceThe oncologist
